Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
Back

[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake

Completed

Open to: ALL

Age: 18.0 - N/A

Cambridge

Medical Conditions

Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


First in Human (FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), distribution, radiation dosimetry, and anti-tumor activity of \[177Lu\]-NeoB in patients with advanced solid tumors known to overexpress GRPR and with \[68Ga\]-NeoB lesion uptake.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

May 2019 Jan 2025

Publications

"Taunk NK, Escorcia FE, Lewis JS, Bodei L. Radiopharmaceuticals for Cancer Diagnosis and Therapy: New Targets, New Therapies-Alpha-Emitters, Novel Targets. Cancer J. 2024 May-Jun 01;30(3):218-223. doi: 10.1097/PPO.0000000000000720."; "38753757"; "Sundlov A, Sjogreen-Gleisner K. Peptide Receptor Radionuclide Therapy - Prospects for Personalised Treatment. Clin Oncol (R Coll Radiol). 2021 Feb;33(2):92-97. doi: 10.1016/j.clon.2020.10.020. Epub 2020 Nov 12."; "33189510"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : \[177Lu\]-NeoB: peptide receptor radionuclide therapy

Intervention Arm Group : Phase I Cohort 1 (DL1(50mCi + 150mCi);Phase I Cohort 2 (DL2 200mCi);Phase I Cohort 3 (DL3 250mCi);Phase II Cohort A (Breast Cancer);Phase II Cohort B (Prostate Cancer);Phase II Cohort C (Gastro Intestinal Stromal Tumor (GIST));Phase II Cohort D (Renal Impairment);Phase II Cohort E (Breast, Prostate, GIST);

Intervention Type : DRUG
Intervention Description : \[68Ga\]-NeoB radioactive diagnostic agent

Intervention Arm Group : Phase I Cohort 1 (DL1(50mCi + 150mCi);Phase I Cohort 2 (DL2 200mCi);Phase I Cohort 3 (DL3 250mCi);Phase II Cohort A (Breast Cancer);Phase II Cohort B (Prostate Cancer);Phase II Cohort C (Gastro Intestinal Stromal Tumor (GIST));Phase II Cohort D (Renal Impairment);Phase II Cohort E (Breast, Prostate, GIST);

Intervention Type : DRUG
Intervention Description : dose strength 49/51 mg, film-coated tablets for oral use

Intervention Arm Group : Phase II Cohort E (Breast, Prostate, GIST);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Addenbroke's hospital
    Cambridge


The study is sponsored by Advanced Accelerator Applications



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT03872778
Last updated 26 January 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top